Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Study of Brentuximab Vedotin in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Treated With Gemcitabine Followed by Brentuximab Vedotin Maintenance

Next Previous
Trial Profile

A Phase II Study of Brentuximab Vedotin in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Treated With Gemcitabine Followed by Brentuximab Vedotin Maintenance

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 12 Jan 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Brentuximab vedotin (Primary) ; Gemcitabine
  • Indications Peripheral T-cell lymphoma
  • Focus Therapeutic Use
  • Acronyms TOTAL

Most Recent Events

  • 09 Jan 2023 Status changed from active, no longer recruiting to completed.
  • 13 Dec 2022 Results of final analysis of this study, presented at the 64th American Society of Hematology Annual Meeting and Exposition
  • 01 Dec 2022 According to a Seagen media release, data from the study will be featured at the upcoming 64th American Society of Hematology (ASH) Annual Meeting and Exposition.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top